Market News & Trends
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Nasus Pharma Ltd. recently announced the successful initiation of the Company's Phase 2 clinical study with dosing of the first participant in Canada. The trial…
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
Agomab Therapeutics NV recently announced positive data from 103 participants completing 12 weeks of treatment in the STENOVA1 Phase 2a clinical trial for ontunisertib (AGMB-129),…
One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors
One-carbon Therapeutics AB recently announced the first subject has been successfully dosed in its ODIN Phase 1/2 clinical trial (NCT07151040) evaluating TH9619, a first-in-class MTHFD1/2…
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People With Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the first participant has been dosed in the open-label extension (OLE) portion of its Phase 2 ALTITUDE-AD clinical trial evaluating…
LifeMD to Offer Market-Leading Pricing for GLP-1 Medications Wegovy & Ozempic in Continued Collaboration With Novo Nordisk
LifeMD, Inc. recently announced a new, lower cash-pay price for GLP-1 medications, Wegovy and Ozempic, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will…
Halda Therapeutics Announces Acquisition by Johnson & Johnson
Halda Therapeutics recently announced it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire Halda for $3.05 billion, payable in…
Azurity Pharmaceuticals & Sebela Pharmaceuticals Announce the Sale of Sebela’s Bowel Prep Franchise to Azurity
Azurity Pharmaceuticals and Sebela Pharmaceuticals announced today Azurity’s successful acquisition of Sebela’s Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies. Ronald Scarboro,…
AEON Biopharma Reports Positive & Robust Biosimilarity Results: Identical Amino Acid Sequence & Highly Similar Functional Analysis Data
AEON Biopharma, Inc., a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, recently announced…
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented
Moleculin Biotech, Inc. recently provided an enrollment update with 60% of the target number of subjects for the first planned interim unblinding of data having consented…
Adagene Announces Licensing Agreement With Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody Technology
Adagene Inc. and Third Arc Bio, Inc. recently announced a licensing agreement under which Third Arc Bio will utilize Adagene’s SAFEbody technology platform to generate…
Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension to the FDA
Cereno Scientific, an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, recently announced the submission of…
Novartis Opens New Radioligand Therapy Manufacturing Facility as Part of $23B US Expansion Plan
Novartis, a leading global innovative medicines company, today announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California. This state-of-the-art…
Nanoform Finland Plc | Inside Information
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced that it has received a Commercial cGMP Manufacturing License from FIMEA (Finnish…
Abzena and Mabqi Announce Strategic Partnership to Offer Integrated Discovery Through Development Solution
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human…
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program
HCW Biologics Inc. recently announced the data presented for their tetra-valent, second-generation T-Cell Engager (“TCE”) Program based on their novel TRBC platform technology, at the…
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator
Assembly Biosciences, Inc. recently announced Phase 1b clinical data for its next-generation investigational capsid assembly modulator (CAM) ABI-4334 featured in a late-breaking poster presentation at…
H&T Presspart Acquires Majority Stake in Plas-Tech Engineering
H&T Presspart, a division of the Heitkamp & Thumann Group, has reached agreement to acquire a majority stake in Plas-Tech Engineering, a privately-owned medical device…
Ocular Therapeutix Achieves Target Randomization of 555 Subjects in SOL-R
Ocular Therapeutix, Inc. recently announced that its SOL-R registrational trial of AXPAXLI™ (also known as OTX-TKI) in wet age-related macular degeneration (wet AMD) has achieved…
Argonaut Manufacturing Services Appoints Rick Hancock as CEO to Lead Next Phase of Growth
Argonaut Manufacturing Services recently announced the appointment of Rick Hancock as Chief Executive Officer (CEO). Rick is a biotechnology executive with more than 40 years…
Enara Bio’s DARKFOX Discovery Propels ENA101, the First Ever Bispecific T Cell Engager Targeting a Cancer-Specific Dark Antigen, Into IND-Enabling Studies
Enara Bio recently will unveil its newly discovered cancer-specific target DARKFOX as the first in a new category of validated Dark Antigens in an oral…
